Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22826756 | 0.87 | ADORA2A (0.59) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL2775140 | 0.82 | ADORA2A (0.71) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL25712959 | 0.81 | LMNA (0.59) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL3239663 | 0.81 | LMNA (0.59) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL7435133 | 0.80 | LMNA (0.58) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL5040895 | 0.80 | ADORA2A (0.98) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13085938 | 0.80 | ADORA2A (0.50) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL5548925 | 0.79 | LMNA (0.57) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9601706 | 0.79 | LMNA (0.57) | ADORA2AALDH1A1LMNAALBMAPK1 | |
| SCHEMBL22862138 | 0.79 | LMNA (0.58) | ADORA2AALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009461-A1 | Therapeutic compounds | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ALDH1A1 764/4885LMNA 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.